Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Raltegravir monotherapy and in combination with Etravirine in patient with virological failure and treatment-experienced but had not previously received RAL or another integrase strand-transfer inhibitor.

Trial Profile

Efficacy of Raltegravir monotherapy and in combination with Etravirine in patient with virological failure and treatment-experienced but had not previously received RAL or another integrase strand-transfer inhibitor.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etravirine (Primary) ; Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Sep 2017 New trial record
    • 01 Aug 2017 Results assessing efficacy of raltegravir as monotherapy and in combination with etravirine in patient with virological failure and treatment-experienced but had not previously received RAL or another integrase strand-transfer inhibitor, were published in the JAIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top